-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharmaceutical announced that the company and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. have recently received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-4729 injections and will conduct clinical trials in the near future. HRS-4729 injection is a polypeptide drug independently developed by the company. It is a GLP-1R/GIPR/GCGR triagonist. It has now been approved to conduct phase II clinical trials on adult type 2 diabetics. Up to now, the project has invested about 81.6 million yuan in R&D.

Zhitongcaijing·08/12/2026 08:41:11
Listen to the news
Hengrui Pharmaceutical announced that the company and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. have recently received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-4729 injections and will conduct clinical trials in the near future. HRS-4729 injection is a polypeptide drug independently developed by the company. It is a GLP-1R/GIPR/GCGR triagonist. It has now been approved to conduct phase II clinical trials on adult type 2 diabetics. Up to now, the project has invested about 81.6 million yuan in R&D.